Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab via SelfDose Device in Plaque Psoriasis
NCT02905331Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of guselkumab in plaque psoriasis, sponsored by Janssen Pharmaceutical. Started Feb 2017; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02905331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905331.